MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures

BackgroundThe presence of MLL rearrangements in acute leukemia results in a complex number of biological modifications that still remain largely unexplained. Armstrong et al. proposed MLL rearrangement positive ALL as a distinct subgroup, separated from acute lymphoblastic (ALL) and myeloblastic leukemia (AML), with a specific gene expression profile. Here we show that MLL, from both ALL and AML origin, share a signature identified by a small set of genes suggesting a common genetic disregulation that could be at the basis of mixed lineage leukemia in both phenotypes.MethodsUsing Affymetrix® HG-U133 Plus 2.0 platform, gene expression data from 140 (training set) + 78 (test set) ALL and AML patients with (24+13) and without (116+65) MLL rearrangements have been investigated performing class comparison (SAM) and class prediction (PAM) analyses.ResultsWe identified a MLL translocation-specific (379 probes) signature and a phenotype-specific (622 probes) signature which have been tested using unsupervised methods. A final subset of 14 genes grants the characterization of acute leukemia patients with and without MLL rearrangements.ConclusionOur study demonstrated that a small subset of genes identifies MLL-specific rearrangements and clearly separates acute leukemia samples according to lineage origin. The subset included well-known genes and newly discovered markers that identified ALL and AML subgroups, with and without MLL rearrangements.

[1]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[2]  C. Croce,et al.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.

[3]  G. Kronnie,et al.  Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study , 2008, Leukemia.

[4]  E. Kimby,et al.  TCL1A expression delineates biological and clinical variability in B-cell lymphoma , 2009, Modern Pathology.

[5]  S. Pileri,et al.  PAX5 Expression in Acute Leukemias , 2004, Cancer Research.

[6]  S. Bauer,et al.  Pre‐B lymphocyte‐specific transcriptional control of the mouse VpreB gene , 1992, European journal of immunology.

[7]  W. Hiddemann,et al.  New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes , 2005, Leukemia.

[8]  I. Jurickova,et al.  Expression of interleukin-6 receptors by pediatric acute lymphoblastic leukemia cells with the t(4;11) translocation: a possible target for therapy with recombinant IL6–Pseudomonas exotoxin , 1997, Leukemia.

[9]  P. Hokland,et al.  Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia , 2008, European journal of haematology.

[10]  T. Rabbitts,et al.  The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. , 2005, Seminars in cancer biology.

[11]  F. Locatelli,et al.  Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols , 2005, Leukemia.

[12]  M. Busslinger,et al.  The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP , 1992, Molecular and cellular biology.

[13]  S. Pettersson,et al.  Context-dependent Pax-5 repression of a PU.1/NF-kappaB regulated reporter gene in B lineage cells. , 2001, Gene.

[14]  Michael A. Teitell,et al.  The TCL1 family of oncoproteins: co-activators of transformation , 2005, Nature Reviews Cancer.

[15]  A. M. Morrison,et al.  Identification of BSAP (Pax‐5) target genes in early B‐cell development by loss‐ and gain‐of‐function experiments , 1998, The EMBO journal.

[16]  Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia , 2006, Leukemia.

[17]  Hyo Joon Kim,et al.  AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10 , 2007, Nature Cell Biology.

[18]  R. Aebersold,et al.  The Direct Recruitment of BLNK to Immunoglobulin α Couples the B-Cell Antigen Receptor to Distal Signaling Pathways , 2002, Molecular and Cellular Biology.

[19]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[20]  A. Barberis,et al.  A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. , 1990, Genes & development.

[21]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[22]  Takuma Hayashi,et al.  CD72‐mediated suppression of human naive B cell differentiation by down‐regulating X‐box bindingprotein 1 , 2005, European journal of immunology.

[23]  M. Schebesta,et al.  Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. , 2002, Immunity.

[24]  J. Iida,et al.  Spreading and Focal Contact Formation of Human Melanoma Cells in Response to the Stimulation of Both Melanoma-associated Proteoglycan (NG2) and α4β1 Integrin , 1995 .

[25]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[26]  M. Baer,et al.  C/EBP-related protein 2 confers lipopolysaccharide-inducible expression of interleukin 6 and monocyte chemoattractant protein 1 to a lymphoblastic cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Z-Y Li,et al.  New insight into the molecular mechanisms of MLL-associated leukemia , 2005, Leukemia.

[28]  T. Rabbitts,et al.  The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. , 2002, Trends in molecular medicine.

[29]  J. Hagman,et al.  Roles of EBF and Pax-5 in B lineage commitment and development. , 2002, Seminars in immunology.

[30]  A. Aguzzi,et al.  Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. , 1992, Genes & development.

[31]  M. Busslinger.  Transcriptional control of early B cell development. , 2004, Annual review of immunology.

[32]  M. Campbell,et al.  Transcription of the blk Gene in Human B Lymphocytes Is Controlled by Two Promoters (*) , 1995, The Journal of Biological Chemistry.

[33]  B. Wasylyk,et al.  Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. , 1996, Genes & development.

[34]  P. Aplan,et al.  Chromosomal translocations involving the MLL gene: molecular mechanisms. , 2006, DNA repair.

[35]  J. Iida,et al.  Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. , 1995, Cancer research.

[36]  T. Cotter,et al.  JNK Regulates HIPK3 Expression and Promotes Resistance to Fas-mediated Apoptosis in DU 145 Prostate Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[37]  J. Downing,et al.  Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[38]  D. Begley,et al.  Identification and sequence of human PKY, a putative kinase with increased expression in multidrug-resistant cells, with homology to yeast protein kinase Yak1. , 1997, Gene.

[39]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[40]  T. Rabbitts,et al.  LIM domain proteins in leukaemia and development. , 1993, Seminars in cancer biology.

[41]  K. Miyazaki,et al.  Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells , 2004, British Journal of Cancer.

[42]  Tina N. Davis,et al.  HOXA9 is required for survival in human MLL-rearranged acute leukemias. , 2009, Blood.

[43]  S. Dudoit,et al.  Multiple Hypothesis Testing in Microarray Experiments , 2003 .

[44]  C. Sawyers.  Molecular genetics of acute leukaemia , 1997, The Lancet.

[45]  C. Goodnow,et al.  Regulation of mouse CD72 gene expression during B lymphocyte development. , 1998, Journal of immunology.

[46]  I. Bernstein,et al.  MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. , 1997, Blood.

[47]  D. Fearon,et al.  Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. , 1997, Journal of immunology.

[48]  S. Bicciato,et al.  Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification , 2003, Leukemia.

[49]  S. Tomita,et al.  BLNK is associated with the CD72 / SHP‐1 / Grb2 complex in the WEHI231 cell line after membrane IgM cross‐linking , 2000, European journal of immunology.

[50]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[51]  B. Schäfer,et al.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.

[52]  S. Desiderio,et al.  Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. , 1994, The Journal of biological chemistry.

[53]  D. Grier,et al.  HOX GENES: Seductive Science, Mysterious Mechanisms , 2006, The Ulster medical journal.

[54]  D. Campana,et al.  An essential role for BLNK in human B cell development. , 1999, Science.

[55]  Harinder Singh,et al.  Genetic networks that regulate B lymphopoiesis , 2005, Current opinion in hematology.

[56]  A. Leutz,et al.  The LIM domain protein Lmo2 binds to AF6, a translocation partner of the MLL oncogene , 2002, FEBS letters.

[57]  J. Rowley.  Molecular genetics in acute leukemia , 2000, Leukemia.